Prof Andersson is a leading researcher in the field of cancer drug development Appointment strengthens Race’s management team Prof Andersson to advise on clinical strategy, partnership initiatives and trial management 5 December 2019 – Race Oncology Limited (ASX: RAC) is honoured…
New clinical strategy targeting five cancer market segments Expanded total addressable market for Bisantrene Bisantrene trials in AML, breast cancer, and ovarian cancer 14 November 2019 – Race Oncology Limited (ASX: RAC) today revealed its new “5 Path” clinical strategy for…
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019. Dr Tillett recently anchored a share placement in RAC and was recently appointed as a Non-Executive…
17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd. Dr Daniel Tillett is the founder…
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett. The placement comprised 21.9 million new ordinary shares at an issue price of $0.066 (6.6 cents) per…
Race Oncology has announced it has secured a new patent on its cancer drug, Zantrene®, from the United States Patent and Trademarks Office (USPTO). This is Race’s third patent granted on Zantrene in the United States. “The new US patent…
Race Oncology is pleased to announce it has successfully completed treatment on its first patient at the Sheba Medical Center in Israel as part of its Bisantrene trial at the facility. The patient diagnosed with relapsed/refractory Acute Myeloid Leukaemia (AML)…
Race Oncology has announced that it has signed an agreement to conduct a trial of Race’s cancer drug, Bisantrene, at the Sheba Medical Center in Israel. The trial has been approved by the Israeli Ministry of Health and the hospital’s…
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene. Roland B. Walter, MD PhD MS, is a leading international haematologist and AML expert, based at…
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas. Under the initial 12-month agreement, Professor Andersson will be engaged to: Advise Race Oncology…
